KIT and gastrointestinal stromal tumor: Other treatments that were considered for the patient were off-label use of ripretinib, which was FDA approved in 2020 for the treatment of advanced GIST, and is highly potent against KIT V560D (with IC50 of 4 ± 1.8 nmol), regorafenib, which is also highly potent against KIT V560D (with IC50 of 4.7 nmol), and cladribine [19, 20].